• Glasgow: The Glasgow Manifesto International Coalition of Older People with HIV (iCOPe HIV) - (10/26/22)
   
  
• NYS People Aging with HIV (PAWH) Pilot (NYC too) - (11/21/22)
   
  
• Glasgow: Efficacy and Safety of Switching to Dolutegravir Plus Rilpivirine in Virologically Suppressed Older PLWH: Pooled Week 148 Results From SWORD-1 and SWORD-2 - (11/17/22)
   
  
• Glasgow: Efficacy and Safety of Dolutegravir/Lamivudine (DTG/3TC) in Black and Asian Participants From TANGO and SALSA: Pooled 48-Week Data Analyzed by Race - (11/17/22)
   
  
• Glasgow: Effectiveness of Dolutegravir + Lamivudine in Real-world Studies in People With HIV-1 With M184V/I Mutations: A Systematic Review and Meta-analysis - (11/17/22)
   
  
More HIV Articles...
 

• HEPATITIS D INFECTION: who should be screened AASLD 2018 HBV Guidelines
   
  
• AASLD: Bulevirtide Improves Health-Related Quality of Life Measured by EQ-5D VAS in Patients With Chronic Hepatitis Delta: An Exploratory Analysis of a Phase 3 Trial at 48 Weeks - (11/15/22)
   
  
• AASLD: Compassionate use of subcutaneously administered REP 2139-Mg in cirrhotic HBV / HDV co-infection - (11/14/22)
   
  
• AASLD: Evaluating Hepatitis Delta Virus Disease Prevalence and Patient Characteristics Among Hospitalized Adults in Italy - (11/14/22)
   
  
• AASLD: Impact of Reflex Testing on the Delta Hepatitis Disease Burden in France - (11/14/22)
   
  
• AASLD: Bulevirtide Improves Health-Related Quality of Life Measured by EQ-5D VAS in Patients With Chronic Hepatitis Delta: An Exploratory Analysis of a Phase 3 Trial at 48 Weeks - (11/14/22)
   
  
• AASLD: OVERCOMING BARRIERS TO CARE FOR DELTA INFECTED PATIENTS - (11/14/22)
   
  
More Hep D Articles...
 


---


 
Monkeypox
 

• A Case of Monkeypox Infection in an Unvaccinated HIV-Positive Male in Rural Alabama - (11/15/22)
   
  
• Evidence for "substantial" monkeypox transmission before symptoms - (11/10/22)
   
  
• CDC Update: Monkeypox and HIV - (11/02/22)
   
  
More Monkeypox Articles...
 

• New Study HCV Treatment During Pregnancy - Enrollment Open STORC Study - (11/22/22)
   
  
• AASLD: Hepatocellular Carcinoma: State of the Art - missing is & Post HCV Cure Surveillance in Patients with Cirrhosis ! - (11/21/22)
   
  
• AASLD: Effect of DAA treatment on extrahepatic manifestations incidence: a population-based study in British Columbia, Canada - (11/21/22)
   
  
More Hep C Articles...
 

• AASLD: Tenofovir-DF Therapy Prevents Hepatitis B Vertical Transmission in Highly Viremic Mothers Without HBV Immunoglobulin for Infants - (11/17/22)
   
  
• AASLD: Evaluation of the vebicorvir, NrtI and AB-729 combination in virologically suppressed patients with HBeAg negative chronic hepatitis B virus infection: Interim analysis from an open label Phase 2 study - (11/11/22)
   
  
• AASLD: Combination Treatment with HBV-Targeting GalNAc-siRNA and Small-Molecule PD-L1 Inhibitor Increases HBV Specific Immune Responses in a Chronic Hepatitis B Infection Mouse Model - (11/11/22)
   
  
• AASLD: Hepatitis B viral control maintained during extended follow up of HBeAg- chronic hepatitis B (CHB) subjects who discontinued nucleos(t)ide analogue (NA) therapy after completion of AB-729 treatment, and in HBeAg+ subjects still on NA therapy - (11/11/22)
   
  
More Hep B Articles...
 


---


 
Fatty Liver, NAFLD, NASH
 

• AASLD: Clinical and Histologic Factors Associated with Discordance Between Steatosis grade Derived From Histology Versus MRI-PDFF in Patients with NAFLD - (11/22/22)
   
  
• AASLD: Increase in Liver Stiffness Measurement (Fibroscan) by Vibration-Controlled Transient Elastography is Associated with Poor Clinical Outcomes in NAFLD - (11/22/22)
   
  
• AASLD: MEFIB-Index and MAST-score in assessment of hepatic decompensation in NAFLD- an individual -patient data meta-analysis - (11/22/22)
   
  
• AASLD: 2 New NASH Drugs in Development - (11/22/22)
   
  
• AASLD: Intercept Announces Positive Data in Fibrosis due to NASH from a New Analysis of its Phase 3 REGENERATE Study of Obeticholic Acid (OCA) - press release - (11/22/22)
   
  
• AASLD: PXL065 (DEUTERIUM-STABILIZED R-ENANTIOMER OF PIOGLITAZONE) REDUCES LIVER FAT CONTENT AND IMPROVES LIVER HISTOLOGY WITHOUT PPARy -MEDIATED SIDE EFFECTS IN PATIENTS WITH NASH: ANALYSIS OF A 36 WEEK PLACEBO-CONTROLLED PHASE 2 TRIAL (DESTINY1) - (11/22/22)
   
  
• AASLD: The bispecific anti-FGFR1/KLB agonist antibody bFKB1 attenuates non-alcoholic steatohepatitis and atherosclerosis in Ldlr-/-.Leiden mice - (11/22/22)
   
  
More Fatty Liver Articles...
 

List not necessarily listed here in order of date being held.